Abstract: Objective — to analyze domestic and foreign literature sources on the use of systemic isotretinoin (SI) in the treatment of acne, focus on aspects of the evolution of the isotretinoin molecule, new routes of action and dosing regimens of the drug, the effectiveness of therapy, relapses and prognostic factors of their development. Materials and methods. We conducted the analysis of publications (systematic reviews, clinical trials and observational studies) from the databases of the Vernadskyi National Library of Ukraine, PubMed, MEDLINE, Web of Science and Scopus by June 2023. The search criteria were the words «acne», «systemic therapy», «isotretinoin», «isotretinoin-LIDOSE», «mechanism of action», «efficacy», «daily dose», «cumulative dose», «relapses» and their analogues in the English language. The final choice of 60 sources was based on the author’s judgments about their completeness and significance for solving the goals. Results and discussion. The clinical efficacy of SI is due to its powerful effect on the leading links of the pathogenesis: hyperproliferation of follicular keratinocytes, hyperactivity of sebocytes, excessive colonization of Cutibacterium acnes and immune-mediated inflammation. A comparative analysis of two forms of SI existing in Ukraine was carried out, the advantages of isotretinoin-LIDOSE over standard isotretinoin in clinical practice were determined. It is not possible to draw a clear conclusion about the indications for SI use in acne because there are conflicting recommendations in national guidelines (USA, UK, Canada) and the international consensus of the Global Alliance. At present, in addition to the standard daily doses of SI, a number of regimens have been proposed in the treatment of moderate and mild acne, suggesting a certain reduction in the corresponding doses that decreases the risk of side effects and has sufficient therapeutic efficacy. The advantages and disadvantages of standard, high-dose and low-dose isotretin regimens are described in terms of effectiveness, ...
No Comments.